Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States. Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9
Mladsi D, Barnett CL, Mader G, Russell-Smith TA, Tuson H, Unuigbe A, Bell T. The zero-price conundrum: exploration of scenarios where a clinically effective new drug might not be cost-effective at zero price. Value Health. 2023 Mar;26(3):384-91. doi: 10.1016/j.jval.2023.01.004.
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Gandola AE, Ait Sarkouh R, Orfanos P, Bouisset F, Licitra L, Bourhis J, Mladsi D, Chirila C, Paret K, Barnett C. An early cost-effectiveness analysis of xevinapant in combination with chemo-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck in United States. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Lucas A, Sinha A, Fowler KB, Mladsi D, Barnett C, Samant S, Gibson L. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Cost Eff Resour Alloc. 2019 Oct 3;17(1):21. doi: 10.1186/s12962-019-0189-0
Odom DM, Mladsi DM, Saag KG, Sherif BN, Miles L, Ronquest N, Wang J. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014 Jun;36(6):906-17. doi: 10.1016/j.clinthera.2014.04.012.
Spinner DS, Mladsi D, Walter J, Ziemiecki R, Stafford-Smith M, Taekman J, Faulkner E. Clinical trial learning curves may impact both clinical and economic outcomes and influence health technology assessment and reimbursement decision making. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A356.
Mladsi DM. Developing health economic models for assessing cost-effectiveness and product value. Presented at the 2006 Health Economics Conference; April 28, 2006. London, UK.